Download PDF
Thromb Haemost 1997; 77(06): 1174-1178
DOI: 10.1055/s-0038-1656133
Fibrinolysis
Schattauer GmbH Stuttgart

Streptokinase Entrapment in Interdigitation-Fusion Liposomes Improves Thrombolysis in an Experimental Rabbit Model

W R Perkins
1   The Liposome Company, Inc., 1 Research Way, Princeton, NJ, USA
,
D E Vaughan
2   Cardioiogy Division, Brigham and Womens Hospital and West Roxbury VAMC, Boston, MA, USA
,
S R Plavin
2   Cardioiogy Division, Brigham and Womens Hospital and West Roxbury VAMC, Boston, MA, USA
,
W L Daley
2   Cardioiogy Division, Brigham and Womens Hospital and West Roxbury VAMC, Boston, MA, USA
,
J Rauch
3   The Montreal General Hospital Research Institute, McGill University, Montreal, Quebec, Canada
,
L Lee
1   The Liposome Company, Inc., 1 Research Way, Princeton, NJ, USA
,
A S Janoff
1   The Liposome Company, Inc., 1 Research Way, Princeton, NJ, USA
› Author Affiliations
Further Information

Publication History

Received 14 May 1996

Accepted after revision 10 March 1997

Publication Date:
26 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The successful design of new thrombolytic agents depends on providing these agents with increased clot selectivity. As recently demonstrated (10), entrapment of tissue plasminogen activator into liposomes apparently provided the selective targeting needed to improve the efficacy of this fibrinolytic agent. To test whether liposomal entrapment would benefit streptokinase, a fibrinolytic agent with a different mode of action and inactivation, we compared liposomal streptokinase with free streptokinase in an experimental rabbit model of thrombolysis.

First we adapted a new method to produce liposomes of high entrapment efficiency, termed interdigitation-fusion (IF) liposomes, for the encapsulation of streptokinase. This system was then tested in an in vivo rabbit model of thrombolysis where animals with established clots were infused with either free streptokinase (40,000 U/kg), liposomally entrapped streptokinase, free streptokinase + empty liposomes, or the corresponding amount of empty liposomes or saline. Significant differences (p <0.05) in the percent clot lysis were observed between saline control (22.4 ± 3.3%; mean ± S.E.), free streptokinase (36.3 ± 3.4%), and liposomal streptokinase (47.4 ± 1.4%). Importantly, animals treated with empty liposomes experienced a level of thrombolysis (32.4 ± 2.8%) not different to that produced by free streptokinase or empty liposomes plus free streptokinase (38.0 ± 2.0%). We believe the effect of liposomes alone is due to a transient redistribution or margination of circulating platelets.

When tested in rabbits immunized against streptokinase, liposomal (33.8 ± 1.5%) but not free streptokinase (29.3 ± 2.1%) showed significant thrombolytic activity compared to saline (22.4 ± 3.3%) (p <0.05). The thrombolytic activity was comparable to free streptokinase in nonimmunized rabbits. This suggests liposomal streptokinase would have better thrombolytic activity than streptokinase alone and still provide to those patients possessing high levels of anti-streptokinase antibodies (5% of the population) the equivalent degree of therapy expected from free streptokinase.

 

  • References

  • 1 De WoodDA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. New Engl J Med 1980; 303: 897-902
    CrossrefPubMedGoogle Scholar
  • 2 Gosage JR. Acute myocardial infarction:reperfusion strategies. Chest 1994; 106: 1851-1856
    CrossrefPubMedGoogle Scholar
  • 3 Habib GB. Current status of thrombolysis in acute myocardial infarction. Chest 1995; 107: 225-232
    CrossrefPubMedGoogle Scholar
  • 4 Verstraete M, Lijnen HR. Novel thrombolytic agents. Cardiovas Drugs Ther 1994; 08: 801-812
    CrossrefPubMedGoogle Scholar
  • 5 Verstraete M. Advances in thrombolytic therapy. Cardiovas Drugs Ther 1992; 06: 111-124
    CrossrefPubMedGoogle Scholar
  • 6 Lijnen HR, Collen D. Strategies for the improvement of thrombolytic agents. Thromb Haemost 1991; 66: 88-110
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Caride VJ, Zaret BL. Liposome accumulation in regions of experimental myocardial infarction. Science 1977; 198: 735-738
    CrossrefPubMedGoogle Scholar
  • 8 Smalling RW, Feld S, Ramanna N, Amirian J, Felli P, Vaughn WK, Swenson C, Janoff A. Infarct salvage with liposomal prostaglandin E1 administered by intravenous bolus immediately before reperfusion in a canine infarction-reperfusion model. Circulation 1995; 92: 935-943
    CrossrefPubMedGoogle Scholar
  • 9 Nguyen PD, O’Rear EA, Johnson AE, Lu R, Fung BM. Thrombolysis using liposomal-encapsulated streptokinase:an in vitro study. Proc Soc Exp Biol Med 1989; 192: 261-269
    CrossrefPubMedGoogle Scholar
  • 10 Heeremans JLM, Prevost R, Bekkers MEA, Los P, Emeis JJ, Kluft C, Crommelin DJA. Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits:a comparison with free t-PA. Thromb Haemost 1995; 73: 488-494
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Nguyen PD, O’Rear EA, Johnson AE, Patterson E, Whitsett TL, Bhakta R. Accelerated thrombolysis and reperfusion in a canine model of myocardial infarction by liposomal encapsulation of streptokinase. Circulation Res 1990; 66: 875-878
    CrossrefPubMedGoogle Scholar
  • 12 Grignani G, Zucchella M, Brocchieri A, Saporiti A. Current concepts in coronary thrombolysis. Haematologica 1994; 79: 475-482
    PubMedGoogle Scholar
  • 13 Ahl PL, Chen L, Perkins WR, Minchey SR, Boni LT, Taraschi TF, Janoff AS. Interdigitation-fusion:a new method for producing lipid vesicles of high internal volume. Biochim Biophys Acta 1994; 1195: 237-244
    CrossrefPubMedGoogle Scholar
  • 14 Perkins WR, Minchey SR, Ahl PL, Janoff AS. The determination of liposome captured volume. Chem Phys Lipids 1993; 64: 197-217
    CrossrefPubMedGoogle Scholar
  • 15 Chen Jr PS, Toribara TY, Warner H. Microdetermination of phosphorus. Anal Chem 1956; 28: 1756-1758
    CrossrefPubMedGoogle Scholar
  • 16 Jackson KW, Esmon N, Tang J. Streptokinase and staphylokinase. Methods in Enzymology. Ed. Perlman GE, Lorand L. Academic Press Inc; New York: 1980. 80. 387-394
    Google Scholar
  • 17 Vaughan DE, Plavin SR, Schafer Al, Loscalzo J. PGEj accelerates thrombolysis by tissue plasminogen activator. Blood 1989; 73: 1213-1217
    PubMedGoogle Scholar
  • 18 Ahl PL, Roberts P, Stevens R, Bhatia S, Ali S, Meers P, Janoff AS. Enhanced circulation-lifetime of DSPC liposomes:importance of complement opsonization and liposome aggregation. Biophys J 1997; 72: A309
    PubMedGoogle Scholar
  • 19 Vaughan DE, Van HouteE, Declerck PJ, Collen D. Streptokinase-induced platelet aggregation:prevalence and mechanism. Circulation 1991; 84: 84-91
    CrossrefPubMedGoogle Scholar
  • 20 Reinish LW, Bally MB, Loughrey HC, Cullis PR. Interactions of liposomes and platelets. Thromb Haemost 1988; 60: 518-523
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Perkins WR, Minchey SR, Boni LT, Swenson CE, Popescu MC, Pasternack RF, Janoff AS. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim Biophys Acta 1992; 1107: 271-282
    CrossrefPubMedGoogle Scholar
  • 22 Doerschuk CM, Gie RP, Bally MB, Cullis PR, Reinish LW. Platelet distribution in rabbits following infusion of liposomes. Thromb Haemost 1989; 61: 392-396
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Handin RI. Disorders of Platelets and Vessel Wall. In: Harrison’s Principles of Internal Medicine. Wilson JD, Braunwald E, Isselbacher KJ, Peters-dorf RG, Martin JB, Fauci AS, Root RK. (eds). McGraw-Hill, NY: 1991. pp 1500-1505
    Google Scholar
  • 24 Patel HM. Serum opsonins and liposomes:their interaction and opsono-phagocytosis. Crit Rev Ther Drug Sys 1992; 9: 39-90
    PubMedGoogle Scholar
  • 25 Hsu MJ, Juliano RL. Interactions of liposomes with the reticuloendothelial system. II. Nonspecific and receptor mediated uptake of liposomes by mouse peritoneal macrophages. Biochim Biophys Acta 1982; 720: 411-419
    CrossrefPubMedGoogle Scholar
  • 26 Fitzgerald DJ, Catella F, Roy L, Fitzgerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988; 77: 142-150
    CrossrefPubMedGoogle Scholar
  • 27 Verstraete M, Vermylen J, Amery A, Vermylen C. Thrombolytic therapy with streptokinase. Brit Med J 1966; 01: 454-456
    CrossrefPubMedGoogle Scholar